PFO
LGND icon

Pathstone Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

Pathstone Family Office’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29
Closed -$2K – 779
2019
Q1 		$2K Sell
29
-90
-76% -$6.82K ﹤0.01% 777
2018
Q4 		$10K Buy
+119
New +$12.7K ﹤0.01% 329
2017
Q2 		– Sell
-6
Closed – – 533
2017
Q1 		$0 Buy
+6
New +$395 ﹤0.01% 602

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Pathstone Family Office's LGND Position: Q2 2019 in Review

Pathstone Family Office sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 29 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in LGND in Q1 2017 and held it in 3 quarters. The position peaked at $10K in Q4 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • Pathstone Family Office reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 29 Ligand Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Pathstone Family Office first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Pathstone Family Office's Ligand Pharmaceuticals position peaked at $10K in Q4 2018.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.